95 related articles for article (PubMed ID: 10953350)
1. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo.
Nagayama Y; Shigematsu K; Namba H; Zeki K; Yamashita S; Niwa M
Anticancer Res; 2000; 20(4):2723-8. PubMed ID: 10953350
[TBL] [Abstract][Full Text] [Related]
2. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE
Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082
[TBL] [Abstract][Full Text] [Related]
3. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells.
Castle VP; Dixit VM; Polverini PJ
Lab Invest; 1997 Jul; 77(1):51-61. PubMed ID: 9251678
[TBL] [Abstract][Full Text] [Related]
5. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F
Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307
[TBL] [Abstract][Full Text] [Related]
6. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.
Filleur S; Courtin A; Ait-Si-Ali S; Guglielmi J; Merle C; Harel-Bellan A; Clézardin P; Cabon F
Cancer Res; 2003 Jul; 63(14):3919-22. PubMed ID: 12873985
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line.
Narimatsu M; Nagayama Y; Akino K; Yasuda M; Yamamoto T; Yang TT; Ohtsuru A; Namba H; Yamashita S; Ayabe H; Niwa M
J Clin Endocrinol Metab; 1998 Oct; 83(10):3668-72. PubMed ID: 9768682
[TBL] [Abstract][Full Text] [Related]
8. Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production.
Zeng G; Gao L; Birklé S; Yu RK
Cancer Res; 2000 Dec; 60(23):6670-6. PubMed ID: 11118051
[TBL] [Abstract][Full Text] [Related]
9. [Effects of exogenous wild type p53 on malignant growth of human lung cancer cell line].
Wang H; Lai B; Li J
Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):268-72. PubMed ID: 11326947
[TBL] [Abstract][Full Text] [Related]
10. [Adenoviral vector expressing an antiangiogenic fragment of thrombospondin 1 inhibits the growth of K562 cell xenografts].
Liu P; Wang Y; Yang RC; Cai YL; Han ZC
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(6):485-8. PubMed ID: 12887763
[TBL] [Abstract][Full Text] [Related]
11. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice.
Collinet P; Vereecque R; Sabban F; Vinatier D; Leblanc E; Narducci F; Querleu D; Quesnel B
J Obstet Gynaecol Res; 2006 Oct; 32(5):449-53. PubMed ID: 16984510
[TBL] [Abstract][Full Text] [Related]
12. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma.
Holmgren L; Jackson G; Arbiser J
Oncogene; 1998 Aug; 17(7):819-24. PubMed ID: 9779998
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells.
Hoffmann S; Rockenstein A; Ramaswamy A; Celik I; Wunderlich A; Lingelbach S; Hofbauer LC; Zielke A
Mol Cell Endocrinol; 2007 Jan; 264(1-2):74-81. PubMed ID: 17101211
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.
Deryugina EI; Soroceanu L; Strongin AY
Cancer Res; 2002 Jan; 62(2):580-8. PubMed ID: 11809713
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo.
Nagayama Y; Yokoi H; Takeda K; Hasegawa M; Nishihara E; Namba H; Yamashita S; Niwa M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4081-6. PubMed ID: 11095436
[TBL] [Abstract][Full Text] [Related]
17. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth.
Nör JE; Christensen J; Liu J; Peters M; Mooney DJ; Strieter RM; Polverini PJ
Cancer Res; 2001 Mar; 61(5):2183-8. PubMed ID: 11280784
[TBL] [Abstract][Full Text] [Related]
18. RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo.
Claudio PP; Stiegler P; Howard CM; Bellan C; Minimo C; Tosi GM; Rak J; Kovatich A; De Fazio P; Micheli P; Caputi M; Leoncini L; Kerbel R; Giordano GG; Giordano A
Cancer Res; 2001 Jan; 61(2):462-8. PubMed ID: 11212232
[TBL] [Abstract][Full Text] [Related]
19. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis.
Gautam A; Densmore CL; Melton S; Golunski E; Waldrep JC
Cancer Gene Ther; 2002 Jan; 9(1):28-36. PubMed ID: 11916242
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
